Global | January 2026 — Novartis AG advanced its strategic portfolio in 2025 with multiple product approvals and commercial launches across oncology, neuroscience, ophthalmology, and rare diseases, reinforcing the company’s commitment to innovation-led, sustainable growth. The year marked significant progress in delivering next-generation therapies to patients worldwide, while laying the foundation for future expansion into 2026 and beyond.
Oncology Portfolio: Driving Innovation in Hematology and Solid Tumors
Kymriah® — CAR-T Therapy
Conditions: Relapsed or refractory B-cell malignancies
In 2025, Novartis expanded Kymriah’s reach globally, with additional approvals in key markets and increased access programs.
Strategic Impact:
Kymriah anchors Novartis’ cell and gene therapy leadership, enabling differentiation in high-value oncology segments.
Scemblix® — Chronic Myeloid Leukemia (CML)
Condition: Philadelphia chromosome-positive CML
Scemblix saw expanded label adoption and international launch activity in 2025, supporting Novartis’ strategy to strengthen its precision oncology portfolio.
Neuroscience Portfolio: Addressing Unmet CNS Needs
Qelbree® — ADHD
Condition: Attention-deficit/hyperactivity disorder in children and adolescents
Following regulatory approval in 2025, Qelbree expanded into additional countries, enabling Novartis to grow its presence in CNS therapeutics beyond traditional adult populations.
Aimovig® and Zolgensma® — Migraine and SMA
Conditions: Migraine prevention, spinal muscular atrophy
Novartis reinforced its leadership in rare and high-impact CNS conditions, leveraging 2025 approvals to broaden patient access globally.
Strategic Impact:
Neuroscience launches provide specialty revenue growth and enhance Novartis’ innovation credibility.
Ophthalmology and Rare Disease
Beovu® — Neovascular Age-Related Macular Degeneration (nAMD)
Condition: Wet AMD
Novartis continued Beovu® rollout in key markets, including additional regulatory approvals in 2025, strengthening its ophthalmology franchise.
Zolgensma® — SMA Gene Therapy
Condition: Spinal muscular atrophy
Zolgensma maintained strong uptake in 2025, reflecting Novartis’ leadership in first-in-class gene therapy for rare pediatric diseases.
Digital, AI, and R&D Enablement
Novartis leveraged AI-driven drug discovery, predictive analytics, and real-world evidence in 2025 to:
- Accelerate trial design and patient stratification
- Enhance commercial forecasting and launch efficiency
- Improve decision-making for global portfolio prioritization
Strategic Impact:
AI adoption enhances development productivity, enabling faster delivery of innovative therapies to patients.
Looking Ahead: 2026 and Beyond
Novartis enters 2026 with:
- Strengthened oncology and cell/gene therapy platforms
- Expanded CNS and rare disease leadership
- Data- and AI-enabled capabilities to optimize future R&D and commercial impact
The company’s 2025 approvals and launches reinforce Novartis’ ability to deliver innovation, drive global patient access, and generate sustainable growth.
Conclusion
Novartis’ 2025 execution demonstrates its commitment to precision medicine, rare diseases, and next-generation therapies. With multiple regulatory and commercial milestones, the company is well-positioned to deliver impactful growth and advance patient care well into 2026 and beyond.
By
